Comparative Pharmacology
Head-to-head clinical analysis: VANCOCIN HYDROCHLORIDE versus VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VANCOCIN HYDROCHLORIDE versus VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER.
VANCOCIN HYDROCHLORIDE vs VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vancomycin inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursor units, thereby preventing polymerization and cross-linking of peptidoglycan.
Inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, blocking transglycosylation and transpeptidation.
15-20 mg/kg IV every 8-12 hours; maximum single dose 2 g. Target trough 10-20 mcg/mL.
15–20 mg/kg IV every 8–12 hours (max 2 g per dose), adjusted based on trough concentrations (target 10–20 mg/L).
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults with normal renal function; prolonged to 7-9 days in anuric patients, necessitating therapeutic drug monitoring.
Terminal half-life: 4-6 hours in adults with normal renal function. Extends significantly in renal impairment (up to 7-10 days in anuria). Requires therapeutic drug monitoring.
Primarily renal (glomerular filtration): 80-90% of dose excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Renal elimination of unchanged drug by glomerular filtration: approximately 80-90% within 24 hours. Biliary/fecal excretion: less than 5%.
Category C
Category A/B
Glycopeptide Antibiotic
Glycopeptide Antibiotic